Inner Peace Meditation
Join Alana Kessler for this reflective and healing guided meditation.
CATEGORIES: Applied Therapeutics | CMT Type - SORD Deficiency | CMT-Connect | CMT-Connect Webinars | Featured
SORD Webinar – Part 2 – Clinical Trial Update
Learn more on this topic
Related Blog Posts
CMT & Balance Webinar
Discuss the balance issues that accompany CMT and review some PT movements to promote improvement.
CMT-Connect Online Essential Oil Webinar March 8, 2017
The benefits of Kundalini Yoga Webinar March 8, 2017
Mobi Mat
Join Brett Gray & Bernadette Scarduzio in their mission to bring accessibility to beaches across the US!
Thermapool Therapy
Therma Pool therapy session and demo as they discuss the benefits of aquatic exercise for CMT and more!
CMT-Connect: January 12, 2017 HNF Takes CMT-Connect On-Line!
HNF is excited to announce our first CMT-Connect Workshop webinar on January 12, 2017 from 7:00-9:00pm.
Are You a Patient With CMT 1A? New Clinical Trial Opportunity Available For You!
For the first time investigators are looking for patients to participate in a pivotal Phase 3 clinical trial of Pharnext’s lead investigational pleodrug, PXT-3003 for the potential treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
CMT and Exercise
HNF wants to help our Inspire members get answers to questions related to Charcot-Marie-Tooth.
Scientific Advisory Board Meeting
On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.
Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A
PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.
0 Comments